

December 15, 2023

Τo

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA

LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – completion of acquisition of marketing and manufacturing related authorisations from Viatris Inc./ Pfizer Inc.

We refer our earlier letters dated July 3, 2023 and September 12, 2023 informing about acquisition of certain marketing and manufacturing related authorisations.

In this regard, we wish to update you that the aforementioned acquisition has been completed on December 15, 2023.

This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your information and dissemination.

Please take the above information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

(CIN: L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED** 

www.aurobindo.com

PAN No. AABCA7366H

 $Corp.\ Off.:\ Galaxy, Floors:\ 22-24, Plot\ No.1, Survey\ No.83/1, Hyderabad\ Knowledge\ City, Raidurg\ Panmaktha, Ranga\ Reddy\ District, Hyderabad\ -\ 500\ 032, Telangana, India.$ 

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.